Cardiac AI: Integrating Diagnostics into Referral Pathways

The digital health field is awash with AI solutions promising to revolutionize cardiovascular care, yet the true measure of their impact often hinges not on technological prowess alone, but on their smooth integration into existing clinical workflows and established reimbursement pathways. Hello Heart’s 10-day early cardiac warning capability, a stark contrast to the traditional 10-year standard clinical risk model and a key factor in its Fast Company 2026 “Most Innovative Companies” recognition, highlights a critical inflection point: the acceleration of diagnostic insights. However, for growth-stage digital health investors, the question remains: how do these non-invasive AI diagnostic tools for coronary artery disease (CAD), particularly those analyzing coronary CT scans, truly integrate into the traditional cardiology referral pathway, and what commercial risks and opportunities does this present?

The Bottleneck of Clinical Adoption: Beyond Technical Accuracy

The narrative around AI in health often centers on its impressive analytical capabilities, identifying subtle patterns, predicting risks, and augmenting diagnostic precision. We see this with companies like Hello Heart, pushing the boundaries of early detection. But for investors, a superior algorithm is only half the story. The other half, arguably the more challenging, involves working through the entrenched realities of healthcare delivery. The commercial viability of even the most sophisticated cardiac AI hinges on how readily it can be adopted by clinicians, and how reliably it can be reimbursed. This means understanding the existing standard of care, the established referral patterns, and the financial incentives (or disincentives) that drive clinical decision-making. Consider the journey of a patient suspected of CAD. Traditionally, this involves a series of steps: primary care evaluation, risk factor assessment, potentially stress testing, and eventually, if indicated, invasive angiography. New AI tools, particularly those analyzing coronary CT angiography (CCTA) scans, aim to optimize this pathway by providing more precise, non-invasive diagnostic information earlier. While the technical accuracy of these AI-powered interpretations can be exceptional, their market success is inextricably linked to their ability to fit into this existing structure without causing significant workflow disruptions or creating new financial burdens for providers. For an AI-native company, this integration is paramount.

Standard of Care Comparisons: Where AI Meets Guidelines

The American College of Cardiology (ACC) clinical guidelines serve as the authoritative blueprint for cardiovascular care. Any new diagnostic tool, regardless of its innovation, must demonstrate alignment with these guidelines to achieve widespread clinical adoption. Investors must scrutinize whether a cardiac AI solution is merely a technological novelty or if it genuinely enhances or simplifies a guideline-recommended diagnostic pathway. Two prominent examples in the cardiac AI diagnostics competitive cluster are HeartFlow and Cleerly. Both use AI to analyze CCTA scans, but their integration into the standard of care, and consequently their commercial trajectory, differs.

• HeartFlow: This SaMD platform provides a non-invasive fractional flow reserve (FFRct) analysis from CCTA images, aiming to identify hemodynamically significant coronary stenoses. HeartFlow has achieved significant traction by integrating directly into established ACC guidelines. The ACC/AHA 2021 Chest Pain Guideline, for example, assigns a Class 2a recommendation for non-invasive functional testing (including CCTA with FFRct) in certain patient populations ACC/AHA 2021 Chest Pain Guideline FFRct recommendation. This explicit guideline inclusion is a powerful de-risking factor for investors, as it signals clinical endorsement and provides a clear pathway for physician adoption. A strong data moat, built on extensive clinical validation, has also contributed to its authority.
• Cleerly: This platform focuses on quantifying coronary plaque burden and characteristics from CCTA, aiming to identify patients at risk of future cardiac events beyond just stenosis. While Cleerly’s approach offers a compelling vision for personalized cardiovascular risk assessment, its direct integration into existing ACC guidelines is still evolving. While CCTA itself is well-established, the specific AI-driven quantification of plaque characteristics as a primary diagnostic or prognostic tool is a newer concept within the guideline framework. This means that while its clinical evidence quality may be strong, its pathway to ubiquitous clinical adoption might require more proactive education and advocacy to shift existing paradigms. The distinction here is important: HeartFlow’s offering directly augments a well-defined diagnostic step (functional assessment of stenosis), making its workflow integration more straightforward. Cleerly, while offering potentially far-reaching insights, introduces a more novel diagnostic model, requiring a greater shift in clinical thinking and potentially a longer adoption curve.
  

  Reimbursement as a Commercial Predictor: The CPT Code Imperative

  Clinical guideline inclusion is a necessary, but not always sufficient, condition for commercial success. Reimbursement pathway clarity is the other critical pillar. The Centers for Medicare and Medicaid Services (CMS) CPT codes are the lingua franca of healthcare billing, and their availability (and the associated payment rates) directly dictates a provider’s willingness to adopt a new technology. Without strong CPT codes, even a guideline-backed innovation can become a zombie company, unable to generate sustainable revenue. For AI-driven CCTA analysis, the presence of specific CPT codes is paramount.

• HeartFlow: Has successfully secured Category I CPT codes for its FFRct analysis (e.g., 0594T, which transitioned to Category I CPT code 75580). This Category I status is a significant advantage, as it signifies permanent coding and generally more stable reimbursement. This clarity allows cardiologists and health systems to confidently integrate HeartFlow into their practice, knowing they will be reimbursed for the service. This exemplifies how a strong regulatory de-risking strategy, culminating in a Category I CPT code, directly impacts market penetration and exit multiples.
• Cleerly: Also has dedicated CPT codes for its quantitative coronary plaque analysis. These analyses transitioned from Category III to Category I CPT code 75577, effective January 2026. The transition from Category III to Category I is a key milestone for any emerging technology, and for Cleerly, this solidifies its market position and reduces commercial risk for investors. CMS CPT codes for coronary CT angiography AI. The difference between Category I and Category III CPT codes is a critical signal for growth-stage investors. Category I codes represent established reimbursement and lower commercial risk, while Category III codes indicate an earlier stage of market acceptance and higher reimbursement uncertainty, despite the potential for future upside.
  

  Workflow Alignment: A Stronger Predictor Than Technical Accuracy

  For growth-stage digital health investors, the takeaway is clear: while technological superiority and compelling clinical outcomes are foundational, the true commercial predictor for cardiac AI diagnostics lies in its smooth workflow alignment and clear reimbursement pathways. A cardiac AI solution that requires significant changes to existing clinical protocols, demands extensive physician training, or lacks clear CPT codes, will face an uphill battle, regardless of its algorithmic sophistication. The market-intel suggests that companies like HeartFlow, which have carefully integrated their SaMD into existing ACC guidelines and secured Category I CPT codes, demonstrate a lower commercial risk profile. They have successfully navigated the patent thicket and built a business model that understands the intricacies of healthcare delivery. Cleerly, while innovative and addressing a significant clinical need, faces the challenge of establishing a new model and transitioning its Category III CPT codes to Category I to achieve broader adoption. The lesson from the competitive cluster of Cardiac AI Diagnostics is that innovation alone is insufficient. The ability to “fit” into the current standard of care, both clinically and financially, is a more strong indicator of market success and potential for strong exit multiples. Investors should prioritize companies that not only push the boundaries of AI in health but also demonstrate a deep understanding of the practical realities of clinical integration and reimbursement.

  Methodology and Source Note

  This analysis is based on a workflow comparative analysis, ranking companies based on their inclusion in American College of Cardiology clinical guidelines and the availability and type of CMS CPT codes for their respective coronary CT angiography AI solutions. Verified references include the latest ACC clinical guidelines and CMS reimbursement databases. The insights presented reflect an evaluation of commercial risk through the lens of workflow integration and reimbursement clarity, grounded in the understanding that these factors are paramount for growth-stage digital health investors. This evaluation is part of the AI Health Innovators Index’s ongoing assessment of the most innovative AI health companies and healthcare AI innovation leaders 2026.